For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- New Govt Panel Holds 1st Meeting for Healthcare, Long-Term Care
October 21, 2016
- MHLW Panel to Discuss Health Coverage of Ethical Drugs with OTC Versions on Oct. 26
October 21, 2016
- Oct. 27 MHLW Panel Meeting Postponed Due to Lack of Quorum
October 21, 2016
- Basic Policy on JP 18th Edition Calls for Expansion of Sections Related to Biopharmaceuticals: MHLW
October 21, 2016
- Heads of Medicines Regulatory Agencies to Hold Summit in Kyoto Next October
October 20, 2016
- Shiozaki Asks for Early Enactment of Clinical Research Bill
October 20, 2016
- MHLW Task Force Calls for Consolidation in Vaccines, Blood Products Industries; “Fundamental to National Security”: Minister
October 20, 2016
- LDP Taskforce Agrees to Squeeze Social Security Budget by 140 Billion Yen
October 19, 2016
- Opdivo Ordered to Add Immune Thrombocytopenic Purpura in ADR List
October 19, 2016
- Concomitant Use of Warfarin and Florid Contraindicated: MHLW
October 19, 2016
- Health Minister Nudges Kaketsuken on Biz Handover to Astellas
October 19, 2016
- Urgent Need for Rule on Interim NHI Price Revisions; Current System Unable to Respond in Case of Add’l Indications: MOF Budget Examiner
October 19, 2016
- MHLW Panel to Review Ono’s Etelcalcetide on Oct. 31
October 18, 2016
- Govt to Stockpile Qinghai Strain Pre-Pandemic Flu Vaccines
October 18, 2016
- Govt Panel Member Pushes 50%-Plus Cut for Opdivo Price
October 17, 2016
- MHLW Panel to Discuss Opdivo for Hodgkin’s Lymphoma on Oct. 27
October 17, 2016
- Huge Costs, Amount of Application Data Required Will Be Major Challenges in Development of Biosimilars: Open Forum
October 14, 2016
- Health Minister to “Positively Consider” Setting Biosimilars Use Target
October 14, 2016
- AMED to Open Office in Washington D.C.
October 13, 2016
- 30% of Rejected Requests for Health Damage Compensation Due to Improper Drug Use: MHLW
October 12, 2016
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…